PDCD2

Across TCGA pan-cancer cohorts, PDCD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDCD2 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PDCD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PDCD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CCRCC show a favorable association.

UCEC, HNSC, and PDAC are the cancer types where PDCD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	III,IV	1.000	0.224	.002	44	view →
HNSC	DFS	Tertile	III,IV	0.625	0.927	<.001	40	view →
PDAC	DFS	Tertile	II,III,IV	0.513	0.841	.018	4	view →
CCRCC	OS	Quartile	II,III,IV	0.760	0.351	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDCD2–UCEC (DFS)

Open the UCEC breakdown →